尿閉治療薬の世界市場レポート 2025年

尿閉治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は6.1％で、52億1,000万米ドルに成長します。予測期間中の成長は、尿閉の有病率の上昇、術後尿閉症例の増加、尿失禁（UI）の発生率の上昇、早期診断・早期治療の利点に対する意識の高まり、前立腺肥大症の有病率の増加などの要因に起因すると考えられます。予測期間における主な動向には、標的ドラッグデリバリーシステム、薬剤製剤、人工知能と機械学習、遠隔医療と遠隔モニタリング、革新的ソリューションの進歩が含まれます。

泌尿器疾患の有病率の増加は、尿閉治療薬市場の拡大を促進すると予想されます。排尿障害は泌尿器系に影響を及ぼす疾患で、排尿困難、痛み、失禁、尿閉などの問題につながります。血糖値の上昇は腎臓や尿路にダメージを与え、糖尿病性腎症や頻回の尿路感染症（UTI）などの症状を引き起こすためです。尿閉症薬は、尿の流れを改善し、膀胱の筋肉を弛緩させ、排尿困難などの症状を緩和することで、快適性と膀胱の機能を向上させ、これらの症状の管理に役立ちます。例えば、2023年10月、イングランドの国民保健サービス（NHS）は、2022/23年に尿路感染症（UTI）を主診断とする14万7,285件の入院を報告しました。これらの症例のうち、65歳以上が56％を占め、総入院数は8万2,392件で、80～84歳が最も多い（1万7,280件）。このような泌尿器疾患の有病率の増加が、尿閉治療薬市場の成長を牽引しています。

尿閉治療薬市場の主なプレーヤーは、患者のコンプライアンスを向上させ、症状を長時間緩和するために、徐放錠などの革新的な製剤の開発に注力しています。徐放性（ER）錠剤は、有効成分を時間をかけて徐々に放出するように設計されており、血中の薬物濃度を一定に保ち、即時放出錠剤と比較して頻繁な投与の必要性を低減します。例えば、2024年4月、インドの製薬会社ザイダス・ライフサイエンシズ・リミテッドが過活動膀胱（OAB）治療薬ミラベグロンのジェネリック医薬品を発売しました。選択的β3アドレナリン作動薬であるミラベグロンは、膀胱の筋肉を弛緩させ、尿意切迫感、頻尿、失禁を軽減します。主にOABに使用されるが、過活動膀胱に関連した尿閉の管理にも役立ちます。1日1回経口投与します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界尿閉治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の尿閉治療薬市場：成長率分析
• 世界の尿閉治療薬市場の実績：規模と成長, 2019-2024
• 世界の尿閉治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界尿閉治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の尿閉治療薬市場：薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• アルファ遮断薬
• ベータ3作動薬
• 抗コリン薬
• 外科用薬剤
• 世界の尿閉治療薬市場：適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 慢性尿閉
• 術後尿閉
• 神経因性膀胱
• 世界の尿閉治療薬市場管理局による、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 注射剤
• 経皮
• 世界の尿閉治療薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• ホームケア
• 専門クリニック
• その他のエンドユーザー
• 世界の尿閉治療薬市場アルファ遮断薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アルファ1遮断薬
• アルファ2遮断薬
• 世界の尿閉治療薬市場、β3作動薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 選択的β3作動薬
• 世界の尿閉治療薬市場抗コリン薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗ムスカリン薬
• 非選択的抗コリン薬
• 世界の尿閉治療薬市場手術薬剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 麻酔薬
• 止血剤
• 筋弛緩剤
• 抗生物質予防

第7章 地域別・国別分析

• 世界の尿閉治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の尿閉治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 尿閉治療薬市場：競合情勢
• 尿閉治療薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bristol-Myers Squibb Company
• AstraZeneca PLC
• Novartis International AG
• GlaxoSmithKline plc
• Medtronic plc
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Teva Pharmaceutical Industries Limited
• Boehringer Ingelheim International GmbH
• Astellas Pharma Inc.
• Sun Pharmaceutical Industries Limited
• Aurobindo Pharma Limited
• Lupin Limited
• Cadila Healthcare Limited
• Torrent Pharmaceuticals Limited

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 尿閉治療薬市場2029：新たな機会を提供する国
• 尿閉治療薬市場2029：新たな機会を提供するセグメント
• 尿閉治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Urinary retention drugs are medications used to treat conditions where patients experience difficulty emptying the bladder, often by relaxing the bladder muscles or stimulating contractions in the bladder to help urine flow. These drugs are commonly prescribed for conditions such as benign prostatic hyperplasia (BPH) or neurogenic bladder, aiming to improve urinary function and relieve discomfort.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main drug classes for urinary retention include alpha blockers, beta-3 agonists, anticholinergics, and surgical agents. Alpha blockers are drugs that work by relaxing the bladder and prostate muscles, helping to improve urine flow and alleviate symptoms of BPH. These medications are used for conditions such as chronic urinary retention, postoperative urinary retention, and neurogenic bladder. They can be administered via oral, injectable, or transdermal routes and are prescribed in various settings, including hospitals, home care, specialty clinics, and others.

The urinary retention drug market research report is one of a series of new reports from The Business Research Company that provides urinary retention drug market statistics, including the urinary retention drug industry global market size, regional shares, competitors with the urinary retention drug market share, detailed urinary retention drug market segments, market trends, and opportunities, and any further data you may need to thrive in the urinary retention drug industry. This urinary retention drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The urinary retention drug market size has grown strongly in recent years. It will grow from$3.87 billion in 2024 to $4.11 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth during the historical period can be attributed to factors such as a rising aging population, increased healthcare investments, advancements in medical infrastructure, a growing geriatric demographic, a global increase in the elderly population, and a higher prevalence of BPH.

The urinary retention drug market size is expected to see strong growth in the next few years. It will grow to$5.21 billion in 2029 at a compound annual growth rate (CAGR) of 6.1%. The growth during the forecast period can be attributed to factors such as the rising prevalence of urinary retention, an increase in postoperative urinary retention cases, a higher occurrence of urinary incontinence (UI), growing awareness of the benefits of early diagnosis and treatment, and the increasing prevalence of benign prostatic hyperplasia. Key trends in the forecast period include advancements in targeted drug delivery systems, drug formulations, artificial intelligence and machine learning, telemedicine and remote monitoring, as well as innovative solutions.

The growing prevalence of urinary disorders is expected to fuel the expansion of the urinary retention drug market. Urinary disorders are conditions that affect the urinary system, leading to issues such as difficulty urinating, pain, incontinence, or retention. The rise in these disorders is largely due to the increasing incidence of diabetes, as elevated blood sugar levels can damage the kidneys and urinary tract, resulting in conditions such as diabetic nephropathy and frequent urinary tract infections (UTIs). Urinary retention drugs help manage these conditions by improving urine flow, relaxing bladder muscles, and alleviating symptoms such as difficulty urinating, thus enhancing comfort and bladder function. For example, in October 2023, the National Health Service (NHS) in England reported 147,285 hospital admissions in 2022/23 with a primary diagnosis of urinary tract infection (UTI). Among these cases, individuals over the age of 65 represented 56%, totaling 82,392 admissions, with the highest number of cases occurring in the 80-84 age group (17,280 cases). This increasing prevalence of urinary disorders is driving the growth of the urinary retention drug market.

Key players in the urinary retention drug market are focusing on the development of innovative formulations such as extended-release tablets to improve patient compliance and offer prolonged symptom relief. Extended-release (ER) tablets are designed to release the active ingredient gradually over time, maintaining a consistent drug concentration in the bloodstream and reducing the need for frequent dosing compared to immediate-release tablets. For instance, in April 2024, Zydus Lifesciences Limited, an India-based pharmaceutical company, launched a generic version of Mirabegron for overactive bladder (OAB). Mirabegron, a selective beta-3 adrenergic agonist, relaxes bladder muscles to reduce urinary urgency, frequency, and incontinence. Although primarily used for OAB, it can also assist in managing urinary retention linked to overactive bladder conditions. The medication is administered as a once-daily oral dose.

In November 2024, Boston Scientific Corporation, a healthcare company based in the U.S., acquired Axonics Inc. for $3.3 billion. This acquisition allows Boston Scientific to expand its urology portfolio by integrating innovative technologies that address urinary and bowel dysfunction. Axonics Inc., a medical technology company based in the U.S., specializes in sacral neuromodulation (SNM) therapy for urinary control. This therapy is used to treat urinary retention and the symptoms of overactive bladder.

Major players in the urinary retention drug market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis International AG, GlaxoSmithKline plc, Medtronic plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Limited, Boehringer Ingelheim International GmbH, Astellas Pharma Inc., Sun Pharmaceutical Industries Limited, Aurobindo Pharma Limited, Lupin Limited, Cadila Healthcare Limited, Torrent Pharmaceuticals Limited, Ajanta Pharma Limited, Ferring Pharmaceuticals Inc., and UroGen Pharma Ltd.

North America was the largest region in the urinary retention drug market in 2024. The regions covered in urinary retention drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the urinary retention drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The urinary retention drugs market consist of sales of tamsulosin (flomax), bethanechol (urecholine), terazosin (hytrin), doxazosin (cardura), finasteride (proscar), and alfuzosin (uroxatral). Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Urinary Retention Drug Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on urinary retention drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for urinary retention drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The urinary retention drug market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Alpha Blockers; Beta-3 Agonists; Anticholinergics; Surgical Agents
• 2) By Indication: Chronic Urinary Retention; Postoperative Urinary Retention; Neurogenic Bladder
• 3) By Administration: Oral; Injectable; Transdermal
• 4) By End Users: Hospitals; Homecare; Specialty Clinics; Other End Users
• Subsegments:
• 1) By Alpha Blockers: Alpha-1 Blockers; Alpha-2 Blockers
• 2) By Beta-3 Agonists: Selective Beta-3 Agonists
• 3) By Anticholinergics: Antimuscarinics; Non-Selective Anticholinergics
• 4) By Surgical Agents: Anesthetics; Hemostatic Agents; Muscle Relaxants; Antibiotic Prophylaxis
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Merck & Co. Inc.; AbbVie Inc.; Sanofi S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Urinary Retention Drug Market Characteristics

3. Urinary Retention Drug Market Trends And Strategies

4. Urinary Retention Drug Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Urinary Retention Drug Growth Analysis And Strategic Analysis Framework

• 5.1. Global Urinary Retention Drug PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Urinary Retention Drug Market Growth Rate Analysis
• 5.4. Global Urinary Retention Drug Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Urinary Retention Drug Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Urinary Retention Drug Total Addressable Market (TAM)

6. Urinary Retention Drug Market Segmentation

• 6.1. Global Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Alpha Blockers
• Beta-3 Agonists
• Anticholinergics
• Surgical Agents
• 6.2. Global Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chronic Urinary Retention
• Postoperative Urinary Retention
• Neurogenic Bladder
• 6.3. Global Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• Transdermal
• 6.4. Global Urinary Retention Drug Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End Users
• 6.5. Global Urinary Retention Drug Market, Sub-Segmentation Of Alpha Blockers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Alpha-1 Blockers
• Alpha-2 Blockers
• 6.6. Global Urinary Retention Drug Market, Sub-Segmentation Of Beta-3 Agonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Selective Beta-3 Agonists
• 6.7. Global Urinary Retention Drug Market, Sub-Segmentation Of Anticholinergics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antimuscarinics
• Non-Selective Anticholinergics
• 6.8. Global Urinary Retention Drug Market, Sub-Segmentation Of Surgical Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anesthetics
• Hemostatic Agents
• Muscle Relaxants
• Antibiotic Prophylaxis

7. Urinary Retention Drug Market Regional And Country Analysis

• 7.1. Global Urinary Retention Drug Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Urinary Retention Drug Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Urinary Retention Drug Market

• 8.1. Asia-Pacific Urinary Retention Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Urinary Retention Drug Market

• 9.1. China Urinary Retention Drug Market Overview
• 9.2. China Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Urinary Retention Drug Market

• 10.1. India Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Urinary Retention Drug Market

• 11.1. Japan Urinary Retention Drug Market Overview
• 11.2. Japan Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Urinary Retention Drug Market

• 12.1. Australia Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Urinary Retention Drug Market

• 13.1. Indonesia Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Urinary Retention Drug Market

• 14.1. South Korea Urinary Retention Drug Market Overview
• 14.2. South Korea Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Urinary Retention Drug Market

• 15.1. Western Europe Urinary Retention Drug Market Overview
• 15.2. Western Europe Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Urinary Retention Drug Market

• 16.1. UK Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Urinary Retention Drug Market

• 17.1. Germany Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Urinary Retention Drug Market

• 18.1. France Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Urinary Retention Drug Market

• 19.1. Italy Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Urinary Retention Drug Market

• 20.1. Spain Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Urinary Retention Drug Market

• 21.1. Eastern Europe Urinary Retention Drug Market Overview
• 21.2. Eastern Europe Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Urinary Retention Drug Market

• 22.1. Russia Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Urinary Retention Drug Market

• 23.1. North America Urinary Retention Drug Market Overview
• 23.2. North America Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Urinary Retention Drug Market

• 24.1. USA Urinary Retention Drug Market Overview
• 24.2. USA Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Urinary Retention Drug Market

• 25.1. Canada Urinary Retention Drug Market Overview
• 25.2. Canada Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Urinary Retention Drug Market

• 26.1. South America Urinary Retention Drug Market Overview
• 26.2. South America Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Urinary Retention Drug Market

• 27.1. Brazil Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Urinary Retention Drug Market

• 28.1. Middle East Urinary Retention Drug Market Overview
• 28.2. Middle East Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Urinary Retention Drug Market

• 29.1. Africa Urinary Retention Drug Market Overview
• 29.2. Africa Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Urinary Retention Drug Market Competitive Landscape And Company Profiles

• 30.1. Urinary Retention Drug Market Competitive Landscape
• 30.2. Urinary Retention Drug Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Urinary Retention Drug Market Other Major And Innovative Companies

• 31.1. Bristol-Myers Squibb Company
• 31.2. AstraZeneca PLC
• 31.3. Novartis International AG
• 31.4. GlaxoSmithKline plc
• 31.5. Medtronic plc
• 31.6. Takeda Pharmaceutical Company Limited
• 31.7. Eli Lilly and Company
• 31.8. Teva Pharmaceutical Industries Limited
• 31.9. Boehringer Ingelheim International GmbH
• 31.10. Astellas Pharma Inc.
• 31.11. Sun Pharmaceutical Industries Limited
• 31.12. Aurobindo Pharma Limited
• 31.13. Lupin Limited
• 31.14. Cadila Healthcare Limited
• 31.15. Torrent Pharmaceuticals Limited

32. Global Urinary Retention Drug Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Urinary Retention Drug Market

34. Recent Developments In The Urinary Retention Drug Market

35. Urinary Retention Drug Market High Potential Countries, Segments and Strategies

• 35.1 Urinary Retention Drug Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Urinary Retention Drug Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Urinary Retention Drug Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250617_r35004_Urinary_Retention_Drug_GMR_2025